Article Sidebar

pdf
Date Published: 25/09/2023
Abstract Views: 134
Views pdf: 118
DOI: https://doi.org/10.51298/vmj.v530i1B.6752
Issue
Vol. 530 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn, A. T., Hoàng, Đào C., Bùi, Q. B., Nguyễn, V. H., Nguyễn, T. V. A., & Trịnh, L. H. (2023). TREATMENT RESULTS OF INTENSITY MODULATED RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY IN STAGE II-III NASOPHARYNGEAL CARCINOMA. Vietnam Medical Journal, 530(1B). https://doi.org/10.51298/vmj.v530i1B.6752

TREATMENT RESULTS OF INTENSITY MODULATED RADIATION THERAPY WITH CONCURRENT CHEMOTHERAPY IN STAGE II-III NASOPHARYNGEAL CARCINOMA

Anh Tuấn Nguyễn1,, Đào Chinh Hoàng1, Quang Biểu Bùi1, Văn Hiến Nguyễn1, Thị Vân Anh Nguyễn1, Lê Huy Trịnh2
1 108 Military Central Hospital
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Objective: To evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CCRT) regimen in stage II-III nasopharyngeal carcinoma (NPC) patients. Methods: A retrospective study on 53 patients stage II-III NPC who underwent IMRT with concurrent chemotherapy; follow-up between October, 2014 to July, 2023. Survival outcomes were assessed using the Kaplan–Meier curves. Results: The mean follow-up time was 55 months (13-106 months). At 1 month after CCRT, the complete and partial response rate were 90,6% and 9,4%, respectively. The 5-year locoregional-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 100%, 91,4%, 91,4%, and 93.7%, respectively. Acute toxicities grade 3-4 occurred in hematologic (Leukopenia 11,3%) and hepatoxicity (15,1% grade 3; 1,9% grade 4). Conclusion: IMRT with concurrent chemotherapy is an effective therapy in stage II-III NPC treatment, with moderate toxicity in hematologic and hepatoxicity.

Article Details

Keywords

Nasopharyngeal carcinoma, concurrent chemoradiotherapy, Intensity Modulated Radiation Therapy (IMRT).

References

1. International Agency for Research on Cancer - World Health Organization. GLOBOCAN 2020: Nasopharynx, accessed May 28-2021, from https://gco.iarc.fr/ today/data/ factsheets/cancers/ 4Nasopharynx-fact-sheet.pdf.
2. Fan Zhang, Yuan Zhang, et al, Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the IntensityModulated Radiotherapy Era: a Propensity-Matched Analysis, Scientific Reports | 5:17378 | DOI: 10.1038/srep17378
3. Lei Wang et al 2021. Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up, Radiat Oncol (2021) 16:215
4. Ting Jin, 2019. Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Patients with Stage II Nasopharyngeal Carcinoma: An Update. doi: 10.1016/j.tranon.2019.08.007
5. Chemotherapy in Combination With Radiotherapy for Definitive-Intent. Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline, J Clin Oncol 39:840-859. © 2021
6. Mete Gundog, 2022. A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. DOI: 10.1016/ j.bjorl. 2019.04.008
7. Trần Thị Kim Phượng, ”Đánh giá kết quả hóa xạ trị đồng thời trong ung thư vòm mũi họng giai đoạn II tại bệnh viện K”, Luận văn tiến sĩ y học. Trường Đại học Y Hà Nội
8. Phạm Lâm Sơn, 2022. ĐÁNH GIÁ KẾT QUẢ HOÁ XẠ TRỊ BỆNH UNG THƯ VÒM HỌNG GIAI ĐOẠN IIB-III BẰNG CISPLATIN HÀNG TUẦN VÀ XẠ TRỊ ĐIỀU BIẾN LIỀU. Tạp chí Y học Việt Nam. Tập 518 Số 2 (2022)
9. NCCN Guidelines Version 2. 2022, Head and Neck Cancers, Cancer of the Nasopharynx, NASO-2
10. ICRU Report 62, Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU 50).